Infections and Infectious Diseases | Preclinical Developments | CANADA

IMV

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

Lead Product(s): DPX-COVID-19

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Majority of 23 peptide epitopes selected by IMV demonstrated robust antibody responses in an animal model after first and second dose in DPX formulation without any additional adjuvant.

Tetra BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program

Lead Product(s): Cannabidiol

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Tetra Bio-Pharma has completed the modifications to the nonclinical safety study of PPP003 to ensure the launch of a Phase 1 trial in healthy volunteers.

Tetra BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome

Lead Product(s): Cannabidiol

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Preclinical proof of concept of PPP003 as potential drug candidate for sepsis demonstrated Tetra to develop PPP003 as potential drug therapy for the battle against COVID-19.

Medicago

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Medicago Announces Production of a Viable Vaccine Candidate for COVID-19

Lead Product(s): Virus-Like Particle

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2020

Details:

Medicago has successfully produced a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene.

XPhyto

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

XPhyto Therapeutics Initiates Infectious Disease Programs

Lead Product(s): Cannabigerol

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

Lead Product(s): Sodium Nitrite,Edetate Disodium

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 21, 2020

Details:

The paper demonstrates key data on the synergistic effects of acidified sodium nitrite and EDTA (active ingredients of AB569) on destroying all bacteria

Mannin Research

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

Platform has been awarded grants from Canada and Europe for its development of therapeutics; additional grant submitted to the STTR program administered by the U.S. National Institutes of Health.

Appili Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats

Lead Product(s): ATI-1701

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

These interim results add to a growing body of evidence supporting advanced development of ATI-1701 as a medical countermeasure against one of the most significant bioterrorism threats.

Find

Find Drugs for Infections and Infectious Diseases in Preclinical Development in CANADA

Canada

A collaboration with SCORR Marketing

Product Type

Companies

IMV

IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

Tetra BioPharma

Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program

Tetra BioPharma

Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome

Medicago

Medicago Announces Production of a Viable Vaccine Candidate for COVID-19

XPhyto

XPhyto Therapeutics Initiates Infectious Disease Programs

Arch Biopartners

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

Mannin Research

Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus

Appili Therapeutics

Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats